EFFECTS OF THE MIXED PHOSPHODIESTERASE III/IV INHIBITOR, ZARDAVERINE, ON AIRWAY FUNCTION IN PATIENTS WITH CHRONIC AIR-FLOW OBSTRUCTION

被引：28

作者：

UKENA, D ^{[1
]}

RENTZ, K ^{[1
]}

REIBER, C ^{[1
]}

SYBRECHT, GW ^{[1
]}

机构：

[1] BYK GULDEN LOMBERG GMBH,D-78467 CONSTANCE,GERMANY

来源：

RESPIRATORY MEDICINE | 1995年 / 89卷 / 06期

关键词：

D O I：

10.1016/0954-6111(95)90214-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Zardaverine is a selective inhibitor of phosphodiesterase (PDE) III and IV isozymes. It has been shown to exert potent bronchodilator effects in animals. In order to study the efficacy and safety in man, a phase II clinical trial in 10 patients with partially reversible chronic airflow obstruction was carried out. The trial was designed as a double-blind, randomized, five-period change-over study. Zardaverine (at single doses of 1.5 mg, 3.0 mg, or 6.0 mg), salbutamol (0.3 mg) and placebo were administered by metered dose inhaler on separate days. As evaluated by spirometry over a time period of 4 h, salbutamol induced a significant bronchodilatation. In contrast, zardaverine did not improve airway function in these patients. Unwanted effects of the study medication were not observed.

引用

页码：441 / 444

页数：4

共 13 条

[1]

BEUME R, 1993, AM REV RESPIR DIS, V147, pA184

[2]

BEUME R, 1987, N-S ARCH PHARMACOL, V355, pR76

[3]

BRUNNEE T, 1992, EUR RESPIR J, V5, P982

[4]

FOSTER RW, 1990, BRIT J PHARMACOL, V99, pP193